Ascendis Pharma's Yorvipath Receives EMA Marketing Authorization for Hypoparathyroidism
Regulatory Approval of Long-Acting Parathyroid Hormone Replacement Therapy
Ascendis Pharma (ASND) has obtained final marketing authorization from the European Medicines Agency (EMA) for Yorvipath (palopegteriparatide), its proprietary treatment for hypoparathyroidism. This approval signifies that the first sustained-release parathyroid hormone (PTH) replacement therapy, designed to maintain stable physiological concentrations for 24 hours in adult patients with chronic hypoparathyroidism, has officially entered the commercialization stage within the European Union (EU). The technical efficacy of the prodrug platform, engineered to act on the parathyroid hormone receptor 1 (PTHR1) via the proprietary TransCon technology, has been validated through rigorous regulatory scrutiny.
Therapeutic Innovation Proven by Pivotal Phase 3 PaTHway Trial
This authorization was granted based on overwhelming efficacy data from the global pivotal Phase 3 clinical trial (PaTHway trial) involving adult patients with chronic hypoparathyroidism. At 26 weeks of treatment, 79% of patients in the Yorvipath group achieved the primary composite endpoint—defined as attaining normal albumin-adjusted serum calcium levels and discontinuation of conventional standard-of-care therapies—compared with only 5% in the placebo group, demonstrating statistical significance (p<0.0001). This result numerically confirms the clinical superiority of controlling severe hypocalcemia symptoms while maintaining uniform drug responsiveness over 24 hours. Patient Quality of Life (QoL) surveys also showed significant improvements in physical and cognitive fatigue compared to the placebo group, providing a positive signal for long-term treatment adherence.
Addressing Unmet Medical Needs Following Natpara's Withdrawal
Previously, hypoparathyroidism patients relied on symptomatic therapies involving high-dose oral calcium and active vitamin D, leaving them constantly exposed to the risks of renal calcification and chronic kidney disease. A significant treatment gap emerged when Takeda’s Natpara (Natpar), the only available hormone replacement, decided to discontinue global supply and withdraw from the market due to manufacturing quality issues, such as rubber particle defects. Yorvipath has secured a decisive foothold to rapidly establish itself as the first and only alternative therapy that corrects the underlying cause of the disease, thereby capitalizing on this market monopoly opportunity. As competing pipelines remain in early clinical stages, the speed of securing standard-of-care status in the European market is expected to accelerate.
Launch of European Direct Sales Network and Prospects for Global Blockbuster Status
Based on this approval, Ascendis Pharma has commenced full-scale product supply by activating its proprietary specialized sales network in key European markets, led by Germany and Austria. The global hypoparathyroidism treatment market is valued at $800 million to $1.1 billion annually and is projected to grow rapidly to over $2 billion by the mid-2030s. While the pace of actual revenue generation will depend on negotiations for national pricing and reimbursement with health authorities, the company is highly advantaged in securing initial market share due to its strong clinical evidence and orphan drug status. This achievement serves as a continuous success story for the commercialization of its platform technology, officially marking the company's transition from an R&D-stage biotech to a commercialized biopharma.
Ascendis Pharma has successfully entered the commercialization stage through the European approval of Yorbivay, which demonstrated a 79% primary endpoint achievement rate in the pivotal Phase 3 PaTHway clinical trial (placebo group 5%, p<0.0001). With Takeda's Natpara, the only existing hormone therapy for hypoparathyroidism, completely halting supply due to manufacturing defects, Orpathy becomes the sole alternative hormone treatment in the global hypoparathyroidism market valued at approximately $800 million to $1.1 billion, enjoying exclusive benefits. In the short term, the penetration rate of the direct sales system in Germany and other European countries launched in January 2024, as well as the results of insurance benefit negotiations in each country, are expected to be key drivers of initial quarterly performance. In the long term, it is firmly positioned to become a blockbuster with peak annual sales exceeding $1 billion in a market projected to expand beyond $2 billion by the mid-2030s, driven by the effects of the U.S. FDA approval obtained in August 2024.
Source: EMA (ema)